KL1333

KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD (P) H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures[1][2].

Product Specifications

CAS Number

[1800405-30-4]

UNSPSC

12352005

Target

Mitochondrial Metabolism; Quinone Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/nqo1-activator-1.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C2N=C(C(C)C)N1)C(C3=C2C=CC=C3)=O

Molecular Formula

C14H12N2O2

Molecular Weight

240.26

References & Citations

[1]Seo KS, et al. KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts. Front Neurol. 2018;9:552. Published 2018 Jul 5.|[2]Lee HS, et al. KL1333, a derivative of β-lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures. Biomed Pharmacother. 2020;126:110068.